KLOW Protocol Prices

KLOW is a marketed four-peptide COMBINATION (blend), not a single compound, it builds on the GLOW blend (BPC-157 + TB-500 + GHK-Cu) by adding KPV for anti-inflammatory action.

The page's own honest framing: there are NO clinical trials, safety studies, or peer-reviewed research on this specific four-peptide combination. Any synergy is theoretical, from the individual components' mechanisms.

PeptidePrices safety rating

7/10 · Not FDA-approved (blend)

Mechanism

Four-peptide combination building on GLOW by adding KPV. A typical 80 mg blend is ~50 mg GHK-Cu, 10 mg TB-500, 10 mg BPC-157, 10 mg KPV (5:1:1:1). Each contributes a separate mechanism: GHK-Cu gene/collagen modulation, TB-500 cell migration and angiogenesis, BPC-157 growth-factor signaling, and KPV NF-kB inhibition (anti-inflammatory). There are no clinical trials on the four-peptide combination.

Research areas

Wound healing; tissue repair; anti-inflammation; skin and recovery support; marketed as a single-injection regenerative blend with added anti-inflammatory action versus GLOW.

Regulatory / research status

Research / preclinical only

Half-life

Varies by component (GHK-Cu ~minutes, BPC-157 ~4 hours, TB-500/KPV longer); a blend has no single half-life.

Storage

Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.

Reported side effects

Injection-site reactions (KPV may reduce these versus GLOW); temporary blue-green skin discoloration (copper); water retention; the main risk is overdosing an individual component. No safety studies exist on the four-peptide combination. Research-use only; not for human consumption.